Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe

References

• World Health Organization. 23-valent pneumococcal polysaccharide vaccine. Position paper. Wkly Epidemiol. Rec.83(42), 373–384 (2008).
   PubMedGoogle Scholar
• Fedson DS, Musher DM. Chapter 22. Pneumococcal polysaccharide vaccine. In: Vaccines. 4th Edition. Plotkin SA, Orenstein WA (Eds). Saunders Elsevier, Philadelphia, PA, USA, 529–588 (2004).
   Google Scholar
• Jackson LA, Neuzil KM. Chapter 24. Pneumococcal polysaccharide vaccines. In: Vaccines. 5th Edition. Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders Elsevier, Philadelphia, PA, USA, 569–604 (2008).
   Google Scholar
• Prato R, Tafuri S, Fortunato F, Martinelli D. Why it is still important that countries know the burden of pneumococcal disease. Hum. Vaccin.6(11), 42–45 (2010).
   Google Scholar
• Changing epidemiology of pneumococcal serotypes after introduction of conjugate vaccine: July 2010 report. Wkly Epidemiol. Rec.85(43), 434–436 (2010).
   PubMedGoogle Scholar
• Michel JP, Chidiac C, Grubeck-Loebenstein B et al. Advocating vaccination of adults aged 60 years and older in Western Europe: statement by the Joint Vaccine Working Group of the European Union Geriatric Medicine Society and the International Association of Gerontology and Geriatrics-European Region. Rejuvenation Res.12(2), 127–135 (2009).
   PubMed Web of Science ®Google Scholar
• Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin. Respir. Crit. Care Med.30(2), 189–209 (2009).
   PubMed Web of Science ®Google Scholar
• Kyaw MH, Rose CE, Fry AM et al.; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J. Infect. Dis.192(3), 377–386 (2005).
   PubMed Web of Science ®Google Scholar
• Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiology of invasive pneumococcal disease in Canada, 1998–2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin. Infect. Dis.49(2), 205–212 (2009).
   PubMed Web of Science ®Google Scholar
• Klemets P, Lyytikäinen O, Ruutu P, Ollgren J, Nuorti J. Invasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies. BMC Infect. Dis.8, 96 (2008).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep.46(RR–8), 1–24 (1997).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC). Recommended adult immunization schedule – United States, 2002–2003. MMWR Morb. Mortal. Wkly Rep.51(40), 904–908 (2002).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP). Prevention of pneumococcal disease among infants and children – use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. MMWR Morb. Mortal. Wkly Rep.59(RR11), 1–18 (2010).
   PubMedGoogle Scholar
• Klemets P, Lyytikäinen O, Ruutu P et al. Risk of invasive pneumococcal infections among working age adults with asthma. Thorax65(8), 698–702 (2010).
   PubMed Web of Science ®Google Scholar
• Michel J-P, Gusmano M, Blank PR, Philp I. Vaccination and healthy ageing, how to make life-course vaccination a successful public health strategy. Eur. Geriatr. Med.1(3), 155–165 (2010).
   Web of Science ®Google Scholar
• Fedson DS, Liss C. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine22(8), 927–946 (2004).
   PubMed Web of Science ®Google Scholar
• Sjöström K, Spindler C, Ortqvist A et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin. Infect. Dis.42(4), 451–459 (2006).
   PubMed Web of Science ®Google Scholar
• Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr. Opin. Pulm. Med.16(3), 217–225 (2010).
   PubMed Web of Science ®Google Scholar
• Brueggemann AB, Griffiths DT, Meats E, Peto T, Crook DW, Spratt BG. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J. Infect. Dis.187(9), 1424–1432 (2003).
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Harboe ZB, Sanders EA et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin. Infect. Dis.51(6), 692–699 (2010).
   PubMed Web of Science ®Google Scholar
• Pletz MW, Welte T, Klugman KP. The paradox of pneumococcal serotypes: highly invasive does not mean highly lethal. Eur. Respir. J.36(4), 712–713 (2010).
   PubMedGoogle Scholar
• Alanee SR, McGee L, Jackson D et al. Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin. Infect. Dis.45(1), 46–51 (2007).
   PubMed Web of Science ®Google Scholar
• Harboe ZB, Thomsen RW, Riis A et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med.6(5), e1000081 (2009).
   PubMed Web of Science ®Google Scholar
• Ardanuy C, Tubau F, Pallares R et al. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997–2007. Clin. Infect. Dis.48(1), 57–64 (2009).
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM et al.; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis.201(1), 32–41 (2010).
   PubMed Web of Science ®Google Scholar
• Vestrheim DF, Høiby EA, Bergsaker MR et al. Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule. Vaccine28(10), 2214–2221 (2010).
   PubMed Web of Science ®Google Scholar
• Rodenburg GD, de Greeff SC, Jansen AG et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, The Netherlands. Emerg. Infect. Dis.16(5), 816–823 (2010).
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH, Boersma C, Postma MJ, Hak E. Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Exp. Rev. Vaccines10(2), 187–199 (2011).
   PubMed Web of Science ®Google Scholar
• Millar EV, Watt JP, Bronsdon MA et al. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin. Infect. Dis.47(8), 989–996 (2008).
   PubMed Web of Science ®Google Scholar
• Greenberg D. The shifting dynamics of pneumococcal invasive disease after the introduction of the pneumococcal 7-valent conjugated vaccine: toward the new pneumococcal conjugated vaccines. Clin. Infect. Dis.49(2), 213–215 (2009).
   PubMedGoogle Scholar
• Hammitt LL, Bruden DL, Butler JC et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J. Infect. Dis.193(11), 1487–1494 (2006).
   PubMed Web of Science ®Google Scholar
• Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine28(26), 4249–4259 (2010).
   PubMed Web of Science ®Google Scholar
• Croucher NJ, Harris SR, Fraser C et al. Rapid pneumococcal evolution in response to clinical interventions. Science331(6016), 430–434 (2011).
   PubMed Web of Science ®Google Scholar
• Veenhoven R, Bogaert D, Uiterwaal C et al. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet361(9376), 2189–2195 (2003).
   PubMed Web of Science ®Google Scholar
• Jansen AG, Rodenburg GD, van der Ende A et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin. Infect. Dis.49(2), e23–e29 (2009).
   PubMed Web of Science ®Google Scholar
• Imöhl M, Reinert RR, van der Linden M. Regional differences in serotype distribution, pneumococcal vaccine coverage, and antimicrobial resistance of invasive pneumococcal disease among German federal states. Int. J. Med. Microbiol.300(4), 237–247 (2010).
   PubMed Web of Science ®Google Scholar
• Imöhl M, Reinert RR, Ocklenburg C, van der Linden M. Association of serotypes of Streptococcus pneumoniae with age in invasive pneumococcal disease. J. Clin. Microbiol.48(4), 1291–1296 (2010).
   PubMed Web of Science ®Google Scholar
• Tsigrelis C, Tleyjeh IM, Lahr BD, Nyre LM, Virk A, Baddour LM. Trends in invasive pneumococcal disease among older adults in Olmsted County, Minnesota. J. Infect.59(3), 188–193 (2009).
   PubMedGoogle Scholar
• Kaplan SL, Barson WJ, Lin PL et al. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics125(3), 429–436 (2010).
   PubMed Web of Science ®Google Scholar
• Hsu KK, Shea KM, Stevenson AE, Pelton SI; Massachusetts Department of Public Health. Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001–2007. Pediatr. Infect. Dis. J.29(4), 289–293 (2010).
   PubMed Web of Science ®Google Scholar
• Hanage WP, Huang SS, Lipsitch M et al. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J. Infect. Dis.195, 347–352 (2007).
   PubMed Web of Science ®Google Scholar
• Hanage WP. Serotype-specific problems associated with pneumococcal conjugate vaccination. Future Microbiol.3(1), 23–30 (2010).
   Web of Science ®Google Scholar
• Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin. Respir. Crit. Care Med.30(2), 210–238 (2009).
   PubMed Web of Science ®Google Scholar
• van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet374(9700), 1543–1556 (2009).
   PubMed Web of Science ®Google Scholar
• Imöhl M, Reinert RR, van der Linden M. Adult invasive pneumococcal disease between 2003 and 2006 in North-Rhine Westphalia, Germany: serotype distribution before recommendation for general pneumococcal conjugate vaccination for children <2 years of age. Clin. Microbiol. Infect.15(11), 1008–1012 (2009).
   PubMed Web of Science ®Google Scholar
• Imöhl M, Reinert RR, van der Linden M. Serotype-specific penicillin resistance of Streptococcus pneumoniae in Germany from 1992 to 2008. Int. J. Med. Microbiol.300(5), 324–330 (2010).
   PubMedGoogle Scholar
• Trotter CL, Waight P, Andrews NJ et al. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996–2006. J. Infect.60(3), 200–208 (2010).
   PubMed Web of Science ®Google Scholar
• Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev.23(1), CD000422 (2008).
   Google Scholar
• Moberley S, Krause V, Cook H et al. Failure to vaccinate or failure of vaccine? Effectiveness of the 23-valent pneumococcal polysaccharide vaccine program in indigenous adults in the Northern Territory of Australia. Vaccine28(11), 2296–2301 (2010).
   PubMedGoogle Scholar
• Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ180(1), 48–58 (2009).
   PubMed Web of Science ®Google Scholar
• Forrester HL, Jahnigan DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high risk population. Am. J. Med.83, 435–430 (1987).
   Google Scholar
• Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann. Intern. Med.108(5), 653–657 (1988).
   PubMed Web of Science ®Google Scholar
• Shapiro ED, Berg AT, Austrian R et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med.325(21), 1453–1460 (1991).
   PubMed Web of Science ®Google Scholar
• Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA270(15), 1826–1831 (1993).
   PubMed Web of Science ®Google Scholar
• Farr BM, Johnston BL, Cobb DK et al. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch. Intern. Med.155(21), 2336–2240 (1995).
   PubMed Web of Science ®Google Scholar
• Benin AL, O’Brien KL, Watt JP et al. Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults. J. Infect. Dis.188(1), 81–89 (2003).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Neuzil KM, Yu O et al.; Vaccine Safety Datalink. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N. Engl. J. Med.348(18), 1747–1755 (2003).
   PubMed Web of Science ®Google Scholar
• Hedlund J, Christenson B, Lundbergh P, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-up. Vaccine21(25–26), 3906–3911 (2003).
   PubMed Web of Science ®Google Scholar
• Andrews RM, Counahan ML, Hogg GG, McIntyre PB. Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia. Vaccine23(2), 132–138 (2004).
   PubMed Web of Science ®Google Scholar
• Dominguez A, Salleras L, Fedson DS et al. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study. Clin. Infect. Dis.40(9), 1250–1257 (2005).
   PubMedGoogle Scholar
• Vila-Corcoles A, Ochoa-Gondar O, Hospital I et al.; EVAN Study Group. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin. Infect. Dis.43(7), 860–868 (2006).
   PubMed Web of Science ®Google Scholar
• Singleton RJ, Butler JC, Bulkow LR et al. Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska native adults. Vaccine25(12), 2288–2295 (2007).
   PubMed Web of Science ®Google Scholar
• Johnstone J, Marrie TJ, Eurich DT, Majumdar SR. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch. Intern. Med.167(18), 1938–1943 (2007).
   PubMedGoogle Scholar
• Mooney JD, Weir A, McMenamin J et al. The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. BMC Infect. Dis.8, 53 (2008).
   PubMedGoogle Scholar
• Spindler C, Hedlund J, Jasir A, Normark BH, Ortqvist A. Effects of a large-scale introduction of the pneumococcal polysaccharide vaccine among elderly persons in Stockholm, Sweden. Vaccine26(43), 5541–5546 (2008).
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Salsench E, Rodriguez-Blanco T et al. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case–control study. Vaccine27(10), 1504–1510 (2009).
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Ochoa-Gondar O, Guzmán JA et al.; EPIVAC Study Group. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older. BMC Infect. Dis.10, 73 (2010).
   PubMed Web of Science ®Google Scholar
• Fedson DS. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: another view of the evidence. Lancet Infect. Dis.3, 272–273 (2003).
   PubMedGoogle Scholar
• Ortqvist A, Hedlund J, Burman LA et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet351(9100), 399–403 (1998).
   PubMed Web of Science ®Google Scholar
• Honkanen PO, Keistinen T, Miettinen L et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine17(20–21), 2493–2500 (1999).
   PubMed Web of Science ®Google Scholar
• Alfageme I, Vazquez R, Reyes N et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax61(3), 189–195 (2006).
   PubMed Web of Science ®Google Scholar
• Maruyama T, Taguchi O, Niederman MS et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ340, c1004 (2010).
   PubMed Web of Science ®Google Scholar
• Dominguez A, Izquierdo C, Salleras L et al.; Working Group for the Study of Prevention of CAP in the Elderly. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly. Eur. Respir. J.36(3), 608–614 (2010).
   PubMed Web of Science ®Google Scholar
• Skull SA, Andrews RM, Byrnes GB et al. Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: Benefit due to influenza and pneumococcal vaccination not demonstrated. Vaccine25, 4634–4640 (2007).
   Google Scholar
• Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch. Intern. Med.159(20), 2437–2442 (1999).
   PubMed Web of Science ®Google Scholar
• Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin. Infect. Dis.42(8), 1093–1101 (2006).
   PubMed Web of Science ®Google Scholar
• Johnstone J, Eurich DT, Minhas JK, Marrie TJ, Majumdar SR. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia. Clin. Infect. Dis.51(1), 15–22 (2010).
   PubMed Web of Science ®Google Scholar
• Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine17(Suppl.), S91–S93 (1999).
   PubMed Web of Science ®Google Scholar
• Hung IF, Leung AY, Chu DW et al. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin. Infect. Dis.51(9), 1007–1016 (2010).
   PubMed Web of Science ®Google Scholar
• Fedson DS. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost–effectiveness. Semin. Respir. Infect.8, 285–293 (1993).
   PubMedGoogle Scholar
• Musher DM, Manof SB, Liss C et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J. Infect. Dis.201(4), 516–524 (2010).
   PubMed Web of Science ®Google Scholar
• Manoff SB, Liss C, Caulfield MJ et al. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = years. J. Infect. Dis.201(4), 525–533 (2010).
   PubMed Web of Science ®Google Scholar
• Musher DM, Sampath R, Rodriguez–Barradas MC. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin. Inf. Dis.52(5), 633–640 (2011).
   PubMed Web of Science ®Google Scholar
• Artz AS, Ershler WB, Longo DL. Pneumococcal vaccination and revaccination of older adults. Clin. Microbiol. Rev.16, 308–318 (2003).
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect. Dis.7, 597–606 (2007).
   PubMed Web of Science ®Google Scholar
• Nichol KL. Pneumococcal vaccination and revaccination in the elderly population. J. Infect. Dis.201(5), 659–661 (2010).
   PubMedGoogle Scholar
• Törling J, Hedlund J, Konradsen HB, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine22(1), 96–103 (2003).
   PubMed Web of Science ®Google Scholar
• de Roux A, Schmöle-Thoma B, Schmöele-Thoma B et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin. Infect. Dis.46(7), 1015–1023 (2008).
   PubMed Web of Science ®Google Scholar
• Väkeväinen M, Soininen A, Lucero M et al.; ARIVAC Consortium. Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination. J. Pediatr.157(5), 778–783 (2010).
   PubMed Web of Science ®Google Scholar
• Dagan R, Givon-Lavi N, Greenberg D, Fritzell B, Siegrist CA. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J. Infect. Dis.201(10), 1570–1579 (2010).
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Bulkow LR, Singleton RJ et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55–74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine9(12), 2287–2295 (2011).
   Google Scholar
• Jackson LA, Benson P, Sneller VP et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA281(3), 243–248 (1999).
   PubMed Web of Science ®Google Scholar
• Walker FJ, Singleton RJ, Bulkow LR, Strikas RA, Butler JC. Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska. Clin. Infect. Dis.40(12), 1730–1735 (2005).
   PubMedGoogle Scholar
• Weinberger DM, Dagan R, Givon-Lavi N, Regev-Yochay G, Malley R, Lipsitch M. Epidemiologic evidence for serotype-specific acquired immunity to pneumococcal carriage. J. Infect. Dis.197(11), 1511–1518 (2008).
   PubMed Web of Science ®Google Scholar
• Baxendale HE, Keating SM, Johnson M, Southern J, Miller E, Goldblatt D. The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly. Vaccine28(30), 4763–4770 (2010).
   PubMed Web of Science ®Google Scholar
• Baxendale HE, Johnson M, Keating SM et al. Circulating pneumococcal specific plasma and memory B cells in the elderly two years after pneumococcal conjugate versus polysaccharide vaccination. Vaccine28(42), 6915–6922 (2010).
   PubMedGoogle Scholar
• Scott DA, Komjathy SF, Hu BT et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine25(33), 6164–6146 (2007).
   PubMed Web of Science ®Google Scholar
• Scott D, Ruckle J, Dar M, Baker S, Kondoh H, Lockhart S. Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults. Pediatr. Int.50(3), 295–299 (2008).
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Andrews N et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50–80 years. Clin. Infect. Dis.49(9), 1318–1325 (2009).
   PubMed Web of Science ®Google Scholar
• Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J. Infect. Dis.198(7), 1019–1027 (2008).
   PubMed Web of Science ®Google Scholar
• Miernyk KM, Butler JC, Bulkow LR et al. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in Alaska native adults 55–70 years of age. Clin. Infect. Dis.49(2), 241–248 (2009).
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Nahm MH, Han MK et al.; COPD Clinical Research Network. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.180(6), 499–505 (2009).
   PubMed Web of Science ®Google Scholar
• Ridda I, Macintyre CR, Lindley R et al. Immunological responses to pneumococcal vaccine in frail older people. Vaccine27(10), 1628–1636 (2009).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Neuzil KM, Nahm MH et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine25(20), 4029–4037 (2007).
   PubMed Web of Science ®Google Scholar
• Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine28(31), 4955–4960 (2010).
   PubMed Web of Science ®Google Scholar
• File TM, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad. Med.122(2), 130–141 (2010).
   PubMed Web of Science ®Google Scholar
• Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax DOI: 10.1136/thx.2009.129502 (2010) (Epub ahead of print).
   Google Scholar
• Ament A, Baltussen R, Duru G et al. Cost–effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin. Infect. Dis.31(2), 444–450 (2000).
   PubMed Web of Science ®Google Scholar
• Evers SM, Ament AJ, Colombo GL et al. Cost–effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur. J. Clin. Microbiol. Infect. Dis.26(8), 531–540 (2007).
   PubMed Web of Science ®Google Scholar
• Smith KJ, Zimmerman RK, Lin CJ et al. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost–effectiveness analysis. Vaccine26(11), 1420–1431 (2008).
   PubMed Web of Science ®Google Scholar
• Smith KJ, Lee BY, Nowalk MP, Raymund M, Zimmerman RK. Cost–effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Vaccine28(48), 7620–7625 (2010).
   PubMed Web of Science ®Google Scholar
• Kawakami K, Ohkusa Y, Kuroki R et al. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine28(43), 7063–7069 (2010).
   PubMed Web of Science ®Google Scholar
• Ogilvie I, Khoury AE, Cui Y, Dasbach E, Grabenstein JD, Goetghebeur M. Cost–effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine27(36), 4891–4904 (2009).
   PubMed Web of Science ®Google Scholar
• Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Cost–effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann. Intern. Med.138(12), 960–968 (2003).
   PubMed Web of Science ®Google Scholar
• Ament A, Fedson DS, Christie P. Pneumococcal vaccination and pneumonia: even a low level of clinical effectiveness is highly cost-effective. Clin. Infect. Dis.33, 2078–2079 (2001).
   PubMed Web of Science ®Google Scholar
• Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part II. A Cost–effectiveness analysis for invasive disease in the elderly in England and Wales. Eur. J. Epidemiol.19(4), 365–375 (2004).
   PubMed Web of Science ®Google Scholar
• Merito M, Giorgi Rossi P, Mantovani J, Curtale F, Borgia P, Guasticchi G. Cost–effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy. Vaccine25(3), 458–465 (2007).
   PubMed Web of Science ®Google Scholar
• Fedson DS. Influenza and pneumococcal vaccination of the elderly: newer vaccines and prospects for clinical benefits at the margin. Prev. Med.23(5), 751–755 (1994).
   PubMedGoogle Scholar
• van Assen S, Elkayam O, Agmon-Levin N et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun. Rev.10(6), 341–352 (2011).
   PubMed Web of Science ®Google Scholar
• Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention (CDC). Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb. Mortal. Wkly Rep.59(34), 1102–1106 (2010).
   PubMedGoogle Scholar
• Bonanni P, Boccalini S, Bechini A. The expected impact of new vaccines and vaccination policies. J. Public Health16(4), 253–259 (2008).
   Google Scholar
• Wahid ST, Nag S, Bilous RW, Marshall SM, Robinson AC. Audit of influenza and pneumococcal vaccination uptake in diabetic patients attending secondary care in the Northern Region. Diabet. Med.18(7), 599–603 (2001).
   PubMedGoogle Scholar
• Gavazzi G, Wazieres B, Lejeune B, Rothan-Tondeur M. Influenza and pneumococcal vaccine coverages in geriatric health care settings in France. Gerontology53(6), 382–387 (2007).
   PubMedGoogle Scholar
• Delelis-Fanien AS, Seite F, Priner M, Paccalin M. Vaccine coverage against influenza and pneumococcal infections in patients aged 65 and over: a survey on 299 outpatients. Rev. Med. Interne30(8), 656–660 (2009).
   PubMedGoogle Scholar
• Tiv M, Clinard F, Guthmann JP et al. Pneumococcal and tetanus vaccination coverage in residents of nursing homes for eldery people in Burgundy and Franche-Comté regions, France, 2009. BEH4, 25–28 (2010).
   Google Scholar
• Martinelli D, Tafuri S, Caputi G et al. Eight years of active proposal of pneumococcal 23-valent polysaccharide vaccine: survey on coverage rate among elderly and chronic patients. Am. J. Infect. Control.38(4), e8–e15 (2010).
   Google Scholar
• Bossuyt N, Van Casteren V. Pneumococcal vaccination coverage in elderly people in Belgium. Arch. Public Health63, 185–198 (2005).
   Google Scholar
• Mereckiene J, Cotter S, O’Donnell J, Igoe D, O’Hora D, O’Flanagan D. Telephone survey to assess uptake of seasonal, pandemic influenza and pneumococcal vaccines in Ireland during the 2009/10 influenza season. Presented at: EuroVaccine Congress. Stockholm, Sweden, 10 December 2010.
   Google Scholar
• Santibanez TA, Zimmerman RK, Nowalk MP, Jewell IK, Bardella IJ. Physician attitudes and beliefs associated with patient pneumococcal polysaccharide vaccination status. Ann. Fam. Med.2(1), 41–48 (2004).
   PubMedGoogle Scholar
• Johnson DR, Nichol KL, Lipczynski K. Barriers to adult immunization. Am. J. Med.121(7 Suppl.), S28–S35 (2008).
   PubMed Web of Science ®Google Scholar
• Kyaw MH, Greene CM, Schaffner W et al. Adults with invasive pneumococcal disease – missed opportunities for vaccination. Am. J. Prev. Med.32(4), 286–292 (2006).
   Google Scholar
• Fedson DS, Houck P, Bratzler D. Hospital based influenza and pneumococcal vaccination: Sutton’s Law applied to prevention. Infect. Control Hosp. Epidemiol.21(11), 692–699 (2000).
   PubMedGoogle Scholar
• Middleton DB, Lin CJ, Smith KJ et al. Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients. Infect. Control. Hosp. Epidemiol.29(5), 385–394 (2008).
   PubMed Web of Science ®Google Scholar
• Rijkers GT, van Mens SP, van Velzen-Blad H. What do the next 100 years hold for pneumococcal vaccination? Expert Rev. Vaccines9(11), 1241–1244 (2010).
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Ochoa-Gondar O, Ester F et al. Evolution of vaccination rates after the implementation of a free systematic pneumococcal vaccination in Catalonian older adults: 4-years follow-up. BMC Public Health6, 231 (2006).
   PubMed Web of Science ®Google Scholar